Combining regorafenib with any Mcl-1 inhibitor markedly lowered regorafenib IC50 and restored regorafenib-induced loss of cell viability, apoptosis, and caspase activation in FBW7-mutant CRC cell lines 6, including SW837, SW48, LoVo, SW1463, HCT-8, and LS411N (Figure 2C-G and Figure S3C-D). Here, MCL1 is linked to colorectal carcinoma.